ClinicalTrials.gg
Active, not recruitingNCT07414394Updated Sep 1, 2026

Tigulixostat (IBI128) vs Febuxostat in Gout

A Phase 3 interventional study of Febuxostat and Tigulixostat in Gout, sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center). Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center) (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.

Enrollment
4th of 44
600 · median 93
Started
2026
with 5 others
Phase 3
9 of 49
none open now
Primary completion
2027-04
later than 9 of 14 live
Registered
43rd of 49
by date

Among the 49 studies in Gout with a site in China, this one is the 4th largest by enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 9 of the 14 other live ones, and was the 43rd registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Gout with a site in China, or all of them as a file.
02

Study summary

The primary purpose of this study is to compare the efficacy of Tigulixostat (IBI128) versus Febuxostat on the proportion of Chinese adults with gout achieving a serum uric acid (sUA) level \< 360 μmol/L at Week 24. The study also evaluates safety, gout attacks, kidney function, inflammation, and quality of life over 52 weeks of treatment. Approximately 600 eligible participants will be randomized to receive either Tigulixostat or Febuxostat.

03

Conditions studied

  • Gout

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for the study:

  1. Age ≥ 18 years, male or female.
  2. (BMI) between 18 and 40 kg/m².
  3. Diagnosed with gout according to the 2015 ACR/EULAR classification criteria.
  4. Serum uric acid (sUA) at screening:

    ≥ 480 μmol/L for subjects without comorbidities;

    ≥ 420 μmol/L for subjects with at least one concurrent condition (e.g., ≥ 2 gout attacks/year, tophi, chronic gouty arthritis, hypertension, diabetes, dyslipidemia, age of onset \< 40 years).

  5. Voluntarily sign the form and agree to strictly follow the protocol requirements.

Exclusion criteria

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from the study:

  1. History of allergy or intolerance to any component of febuxostat or Tigulixostat, or previous evidence of poor response to febuxostat treatment (e.g., sUA > 420 μmol/L after ≥ 6 weeks of febuxostat ≥ 40 mg).
  2. Acute gout attack within 4 weeks prior to screening or from screening to first dose.
  3. Use of uric acid-lowering drugs (e.g., allopurinol, febuxostat, probenecid, benzbromarone, dotinurad, recombinant uricase; excluding sodium bicarbonate) within 2 weeks before screening.
  4. Hyperuricemia caused by secondary gout (e.g., myeloproliferative disease, tumor, organ transplantation, enzyme deficiency, renal tubular dysfunction, lead poisoning, psoriasis, medications), excluding hyperuricemia due to renal insufficiency.
  5. Use of the following medications or therapies prior to screening or planned during the study:

(1)Prior urate oxidase treatment; (2)Concomitant medications affecting uric acid levels within 4 weeks before screening with dose adjustments (e.g., losartan, calcium channel blockers, diuretics, fenofibrate, atorvastatin, α-glucosidase inhibitors, insulin sensitizers, DPP4 inhibitors, SGLT2 inhibitors, metformin, GLP-1 receptor agonists, pyrazinamide, aspirin); (3)Long-term drugs dependent on xanthine oxidase metabolism (e.g., azathioprine, mercaptopurine); (4)Oral ≥ 10 consecutive days, or intramuscular/intravenous/intra-articular corticosteroid injection within 4 weeks before screening; (5)Biologics (e.g., TNF-α inhibitors, IL-1 inhibitors, IL-6 inhibitors) within 12 weeks before screening.

6. History or evidence of any of the following diseases:

  1. Xanthinuria, Lech-Nyhan syndrome, 5-phosphoribosyl-1-pyrophosphate synthetase superactivity, congenital myogenic hyperuricemia, rhabdomyolysis;
  2. Uncontrolled severe pain not caused by gout;
  3. Cardiovascular events or conditions within 6 months (e.g., acute MI, ACS, unstable angina, CABG, PCI, , cerebrovascular accident, severe arrhythmia, class III/IV heart failure);
  4. ≥ 480 ms or history of prolonged QTc interval;
  5. Poorly controlled hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg) or recent adjustment of antihypertensive drugs;
  6. Poorly controlled diabetes ( ≥ 9.0%);
  7. or inflammatory diseases requiring systemic treatment;
  8. Active peptic ulcer or GI bleeding within 1 month;
  9. Diseases affecting drug absorption (e.g., IBS, IBD);
  10. Active , C, , or syphilis infection;
  11. Active or untreated within 5 years, except specified low-risk cancers;
  12. Thyroid dysfunction requiring treatment. 7. Laboratory abnormalities:

(1)total > 2×, or AST > 3×ULN; (2) \< 30 mL/min/1.73 m². 8. Pregnant or lactating women, or participants unwilling to use effective during the study and for 8 weeks after study end.

9. History of alcohol or drug abuse (weekly alcohol > 21 units for males, > 14 units for females).

10. Blood donation or loss ≥ 400 mL within 3 months, or prior blood transfusion.

11. Participation in another interventional clinical trial within 3 months or 5 half-lives of prior drug.

12. Major surgery within 3 months, incomplete recovery, or planned major surgery during study.

13. Presence of mental illness deemed inappropriate for study participation by the investigator.

14. Any other condition judged by the investigator to potentially affect study efficacy or safety evaluation.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    Tigulixostat

    Drug: Tigulixostat

  • Active comparator
    Febuxostat

    Drug: Febuxostat

Interventions

  • Participants in this group receive Febuxostat tablets together with dummy tablets matching Tigulixostat once daily during the 24-week core treatment period. Thereafter, participants switch to Tigulixostat tablets alone once daily during the 28-week extension treatment period.

  • Participants in this group receive Tigulixostat (IBI128) tablets together with dummy tablets matching Febuxostat once daily during the 24-week core treatment period, with dose escalation per protocol. Thereafter, participants continue Tigulixostat tablets alone once daily during the 28-week extension treatment period.

    Also known as: IBI128

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Serum Uric Acid <360 μmol/L at Week 24

    Percentage of participants with serum uric acid (sUA) level below 360 μmol/L at Week 24 after randomized treatment with Tigulixostat (IBI128) or Febuxostat in Chinese participants with gout.

    Time frame: At Week 24

Secondary outcomes

  1. Proportion of Participants Achieving Serum Uric Acid <360 μmol/L at Week 12

    Percentage of participants with serum uric acid (sUA) level below 360 μmol/L at Week 12.

    Time frame: At Week 12

  2. Proportion of Participants with Serum Uric Acid <360 μmol/L at Each Scheduled Visit

    Proportion of participants achieving a serum uric acid (sUA) level \<360 μmol/L at each scheduled visit during the 52-week study period.

    Time frame: At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52

  3. Proportion of Participants Achieving Serum Uric Acid <300 μmol/L at Each Scheduled Visit

    Percentage of participants with serum uric acid (sUA) level below 300 μmol/L at each scheduled visit during the 52-week treatment period.

    Time frame: At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52

  4. Proportion of Participants Achieving Serum Uric Acid <240 μmol/L at Each Scheduled Visit

    Percentage of participants with serum uric acid (sUA) level below 240 μmol/L at each scheduled visit during the 52-week treatment period.

    Time frame: At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52

  5. Mean Change From Baseline in Serum Uric Acid Level at Each Scheduled Visit

    Mean change from baseline in serum uric acid (sUA) level at each scheduled visit during the 52-week treatment period.

    Time frame: At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52

  6. Mean Percent Change From Baseline in Serum Uric Acid Level at Each Scheduled Visit

    Mean percent change from baseline in serum uric acid (sUA) level at each scheduled visit the 52-week treatment period.

    Time frame: At Week 0, 2, 4, 8, 12, 16, 20, 24, 32, 42, and 52

  7. Number of Participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)

    Percentage of participants who have experienced AEs/SAEs.

    Time frame: Baseline through Week 54 (end of safety follow-up)

  8. Proportion and Number of Gout Flares per Participant

    Proportion of participants experiencing gout flares and the number of gout flares per participant during each 4-week interval following initiation of study treatment.

    Time frame: Every 4 weeks from first dose through Week 52

  9. Change From Baseline in Renal Function Parameters

    Change from baseline in estimated glomerular filtration rate (eGFR) at Weeks 12, 24, and 52.

    Time frame: At Week 12, 24, and 52

  10. Change From Baseline in Renal Function Parameters

    Change from baseline in urine albumin-to-creatinine ratio (UACR) at Weeks 12, 24, and 52.

    Time frame: At Weeks 12, 24, and 52

  11. Change From Baseline in Inflammatory and Deposition-Related Parameters

    Change from baseline in urolithiasis status, gouty tophi, and systemic inflammation as assessed by high-sensitivity C-reactive protein (hs-CRP) at Weeks 12, 24, and 52.

    Time frame: At Weeks 12, 24, and 52

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 17, 2026
StartActual
Mar 17, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07414394
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Mar 17, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Sep 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tigulixostat

Start the discussion